MARC Encourages CMS to Ensure Proper Management of Frequently Abused Drugs in Part D

Today, Medicare Advocacy Recovery Coalition (MARC) Chairman Greg McKenna submitted a comment letter to CMS Administrator Seema Verma in response to the proposed rule entitled  “Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program.” In the letter, Chairman McKenna applauded CMS’  initiatives to address the nation’s opioid epidemic, and stressed that CMS must to ensure that frequently abused drugs are appropriately managed so that Medicare beneficiaries at risk of abuse and addiction cannot access them through the Part D program. “We write today to urge CMS in both its final rule and in the final rule preamble to address how frequently abused drugs could be accessed through Workers Compensation Medicare Set Aside arrangements (MSAs),” wrote Chairman McKenna. 

Chairman McKenna also stated: “As CMS is aware, during the MSA process CMS reviews Medicare Secondary Payer proposals for future care, and advises beneficiaries on proposed plans of care. Unfortunately, at a time when the entire federal government is working to curb opioid use, CMS in the MSA process is inadvertently suggesting use be expanded. More specifically, following the submission of MSAs to CMS by beneficiaries or those funding beneficiary care, the Agency often proposes back modifications to care plans. In many cases a beneficiary may need some pain medications, such as an opioid– which if used beyond their medically necessary requirements can lead to addiction and other abuse. Unfortunately, the routine and consistent practice of CMS is to require MSA payment for lifetime use of highly potent and frequently abused drugs. These CMS recommendations are far beyond any evidenced-based guideline recommendations, and could cause harm to the beneficiaries involved if they misconstrue the CMS recommendations as federally sanctioned treatment guidelines or requirements.”

The comment letter in its entirety can be viewed here.

Featured News

  • MARC Coalition Announces 2026 Executive Committee

    December 18, 2025 (Washington, DC) – This week, the MARC Coalition, a national coalition advocating for the improvement of Medicare Secondary Payer (MSP) programs, announced their Executive Committee for 2026.   MARC’s Executive Committee consists of a Chair, Vice Chair, Secretary/Treasurer, and At-Large members. The officers are elected to 2-year terms, and At-Large members are elected to a […]

    Read Article
  • MARC Coalition Hosts Webinar to Discuss the CMS ORM program

    November 17, 2025 (Washington, DC) – The MARC Coalition today hosted a webinar about the CMS ORM program at 1:00pm ET. Presenters included David Farber, Partner at King and Spalding and Brian MacAllister, Senior Medicare Unit Manager – Managed Solutions at Liberty Mutual. Approximately 60 people attended the public webinar, including MARC members and industry stakeholders. […]

    Read Article
  • MARC Announces Introduction of the RAMP Act in 119th Congress

    Washington, DC (June 20, 2025)  Today, the Medicare Advocacy and Recovery Coalition (MARC) celebrated the introduction of the Repair Abuses of MSP Payments Act (RAMP Act, H.R. 4056), introduced in the U.S. House of Representatives by Representative Gus Bilirakis (R-FL) and Representative Brad Schneider (D-IL). The legislation advocates for modernizing the broken and outdated MSP “private cause […]

    Read Article